ORGO | Organogenesis Holdings Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.20 - 3.47
52 Week Range	2.1650 - 4.57
Beta	1.77
Implied Volatility	302.10%
IV Rank	35.11%
Day's Volume	256,384
Average Volume	657,666
Shares Outstanding	125,726,000
Market Cap	403,580,460
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2017-01-05

Valuation
Profitability
Growth
Health
P/E Ratio	-64.20
Forward P/E Ratio	N/A
EPS	-0.05
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	862
Country	USA
Website	ORGO

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.

ORGO's peers: AQST, CPIX, DERM, DRRX, KALA, KMDA, SHPH, MNK, LSDI, ALIM, LFCR, RDHL, TARO, COLL, ADMP, TKNO, GHSI, PTPI, ALKS, NBIX, ITCI, DCPH, DVAX, SCYX, SIGA, TXMD

*Chart delayed

Analyzing fundamentals for ORGO we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is very good and Health is passable. For more detailed analysis please see ORGO Fundamentals page.

Watching at ORGO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on ORGO Technicals page.